展望未來，星曜生醫將搭乘 AI 賦能醫學、長壽經濟崛起的東風，以科技為翼，創新為帆，深度構建“檢測—預防—治療—康復—投資”生態閉環，全力推動“健康資本化”價值轉化。秉持“富在術數，不在勞身；利在勢局，不在立耕”的智慧，憑藉對行業趨勢的深刻洞察，將前沿科技與健康產業完美融合，實現商業價值的最大化變現，開創生命經濟新紀元，為全球健康福祉貢獻磅礴力量！
Amid the rapid growth of the global health industry and the continuous waves of technological advancement, Taiwan Star Rich Biomedical Technology Co., Ltd. is taking a bold step forward in its strategic international expansion. The company has officially announced an active collaboration with Hong Kong MTT Group Holdings Limited. The two parties will hold a grand signing ceremony on April 6 at the International Conference Center, 1st Floor, Formosa Yacht Resort in Tainan, marking the beginning of an exciting new journey. Industry elites will gather at the event, with distinguished guests including Hong Kong MTT Group Holdings Limited’s chief representatives Jin Shengxian, Li Xiaoping , the CEO of Securities company ELLEN, and OLIVIA, Head of the Securities & Mastercard Collective Business Unit. These key figures will witness this milestone moment and engage in discussions about the future of the industry. As a leading player in the health sector, Star Rich Biomedical Technology has been dedicated to the research, development, and sales of health supplements for years. With outstanding quality and an innovative approach, its business footprint spans Taiwan, Japan, Mainland China, Hong Kong, Singapore, Vietnam, Thailand, and beyond, earning the trust of consumers worldwide. In this partnership, Hong Kong MTT Group Holdings Limited’s core IT team will play a pivotal role. On one hand, leveraging cutting-edge technology, they will ensure the stable operation of Star Rich Biomedical Technology’s global business, smoothly integrating supply chain, sales, and customer service. On the other hand, they will make good use of the company’s vast operational data, contributing to innovation and exploring new ways for business growth, providing continuous momentum for Star Rich Biomedical Technology’s expansion. Today, AI technology is reshaping the pattern of medical advancements at an unprecedented pace. From precision medicine targeting diseases at their core to anti-aging research pushing the boundaries of human longevity, we have officially entered the era of the longevity economy. Recognizing this shift, Star Rich Biomedical Technology has taken the lead with exceptional industry foresight. The company has innovatively introduced the “Consumer Data Securitization” strategy—a key that unlocks rapid expansion and has quickly become a hot topic in the capital market. Looking ahead, Star Rich Biomedical Technology will ride the wave of AI-driven medical advancements and the rise of the longevity economy. With technology as its wings and innovation as its sail, the company aims to build a comprehensive ecosystem covering “testing, prevention, treatment, rehabilitation, and investment,” accelerating the transformation of health assets into capital. Guided by the wisdom that “wealth lies in strategy, not in labor; profit comes from positioning, not just effort,” Star Rich Biomedical Technology will leverage deep industry insights to seamlessly integrate cutting-edge technology with the health industry, maximizing commercial value, pioneering the life economy, and contributing to the well-being of people worldwide!